Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CUO
|
|||
| Drug Name |
TTI-621
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [2] | ||
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 1 | [2] | ||
| Mycosis fungoides [ICD-11: 2B01; ICD-10: C84.0] | Phase 1 | [1], [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [3] | ||
| Squamous cell carcinoma [ICD-11: 2B60-2D01; ICD-10: C44; ICD-9: 199] | Phase 1 | [2] | ||
| Company |
Trillium Therapeutics Mississauga, Canada
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen CD47 (CD47) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02890368) Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.